From a chemical compatibility perspective, adding bacteriostatic water to a third-party peptide can produce unpredictable results if the peptide material has an unsuitable pH, contains residues from manufacture, has degraded during storage, or has poor solubility characteristics
Published large human clinical-trial data is not available, so a regulator-grade answer to that question does not exist
My protocol was straightforward: Retatrutide: 4 mg per week, subcutaneous injection (abdomen), every Saturday morning AOD-9604: 0.3 mg per day, subcutaneous injection (abdomen), every morning before eating Duration: 16 weeks of the combined stack Diet: High protein (90 to 100 grams daily), moderate carbs, 30 to 40 grams of healthy fats Activity: Walking 5 days a week, light resistance training 2 days Within the first two weeks of adding AOD-9604, I noticed my midsection felt different
Potential Risks and Controversies While generally mild, theres limited research on BPC 157s long-term effects
According to one owner of an Australian peptides distribution company, more patient requests for peptides are declined [12]: [Particularly] if a patient comes and asks me for a specific peptide and it's not right for them